Pharmaceuticals and Market
Welcome to Unibest's Pharmaceutical Market Intelligence Reports, a comprehensive collection of in-depth analyses on drugs and their respective disease areas. These reports are meticulously crafted to support pharmaceutical companies in making informed decisions about their product portfolios. Our expert team synthesizes data from public databases, proprietary market research, expert interviews, and industry news to provide actionable insights on disease landscapes, unmet medical needs, market size projections, competitive positioning, and regulatory trends. Tailored for industry professionals in strategic planning, business development, market access, and R&D, these reports aim to empower pharmaceutical companies with the intelligence needed to optimize their product strategies and maximize market value. 
  • Cost is King: Why Small Molecule GLP-1 Drugs Are Gaining Popularity in Developing Countries

    Cost is King: Why Small Molecule GLP-1 Drugs Are Gaining Popularity in Developing Countries

    2025-07-09

    This article explores the growing preference for small molecule GLP-1 receptor agonists in developing countries, driven by cost sensitivity, infrastructure limitations, and the need for scalable oral therapies for diabetes and obesity. It examines the economic and clinical advantages of small molecules over biologics, analyzes emerging market dynamics, and outlines how Unibest leverages its sourcing, regulatory, and export expertise to support global access. The piece also reviews current pipeline innovations and the future potential of affordable GLP-1 drugs in underserved regions. Read More
  • Dual Incretin Revolution: Tirzepatide’s Mechanism And Clinical Impact in Obesity & Diabetes

    Dual Incretin Revolution: Tirzepatide’s Mechanism And Clinical Impact in Obesity & Diabetes

    2025-06-19

    Tirzepatide, a dual GIP/GLP-1 receptor agonist, represents a breakthrough in obesity and type 2 diabetes treatment. This article explores its synergistic mechanism, superior clinical outcomes, and global market potential. It also highlights how Unibest supports global pharma companies with API sourcing, licensing, and regulatory services in the incretin drug space. Read More
  • 6 Takeaways from EpimAb's $210 Million NewCo - Case Study

    6 Takeaways from EpimAb's $210 Million NewCo - Case Study

    2025-05-28

    EpimAb Biotherapeutics has successfully implemented the NewCo model through two significant deals in 2024-2025: licensing EMB-06 to Vignette Bio and a T-cell engaging molecule to Juri Biosciences. Read More
  • Future Medications for Obesity

    Future Medications for Obesity

    2025-05-26

    Obesity is a global health crisis affecting over 650 million people worldwide. But there's hope on the horizon. Recent breakthroughs in understanding how our gut and pancreatic hormones regulate appetite and blood sugar have led to the development of exciting new medicines to treat obesity and relat Read More
  • New Approval of Olaparib Indication

    New Approval of Olaparib Indication

    2025-03-10

    New Approval of Olaparib IndicationOn January 2nd, AstraZeneca and Merck jointly announced that their PARP inhibitor Lynparza® (Generic name: olaparib) has received approval for a new indication in China. Read More
  • Lenacapavir - The HIV 'Vaccine'

    Lenacapavir - The HIV 'Vaccine'

    2025-02-07

    The topic of this report is a long-acting HIV "vaccine" called Lenacapavir, developed by Gilead Sciences in the United States. Read More
  • Semaglutide: A Promising Frontier in Alzheimer's Disease Prevention

    Semaglutide: A Promising Frontier in Alzheimer's Disease Prevention

    2024-10-25

    We're excited to discuss groundbreaking research on semaglutide, the blockbuster medication that's showing promising potential in the fight against Alzheimer's disease (AD) Read More
  • Oral SERD Therapy: Elacestrant's Impact on Metastatic Breast Cancer

    Oral SERD Therapy: Elacestrant's Impact on Metastatic Breast Cancer

    2024-10-10

    IntroductionBreast cancer remains a significant global health challenge, with over 2.3 million new cases diagnosed worldwide in 2022, according to the IARC. The disease burden is disproportionately higher in countries with medium or low levels of the Human Development Index (HDI), where access to in Read More
  • Alopecia Areata: More Than Just Hair Loss

    Alopecia Areata: More Than Just Hair Loss

    2024-09-20

    Alopecia areata (AA) is an autoimmune disorder that goes far beyond mere hair loss. While the physical manifestation of patchy or complete hair loss is its most visible symptom, the impact of AA extends deep into the psychological realm, affecting millions worldwide.Understanding Alopecia AreataAlop Read More
  • Total 5 pages  Go to Page
  • Go